Publications

Search or filter publications

Search publications Search

Filter by type:

Filter by publication type

• Book
• Book chapter
• Conference paper
• Journal article
• Other
• Patent
• Poster
• Report
• Scholarly edition
• Software
• Thesis dissertation
• Working paper

Filter by year:

Filter from 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974 to Filter to 20262025202420232022202120202019201820172016201520142013201220112010200920082007200620052004200320022001200019991998199719961995199419931992199119901989198819871986198519841983198219811980197919781977197619751974

---

Search results

• Journal article
  Chung F, 2025,

  Multidrug-resistant Haemophilus influenzae cluster of severe asthma from sputum bacteriome-resistome

  , ERJ Open Research
  • Cite
• Journal article
  Lin Z, Huang J, He L, Xie S, Shu G, Chen G, Lin W, Zhong X, Li S, Chung KF, Chen Ret al., 2025,

  Integrative genomics reveal genetic links of chronic cough with risk factors and brain regional volumes

  , ERJ Open Research, Pages: 00844-2025

  <jats:sec> <jats:title>Objectives</jats:title> <jats:p>Chronic cough is a common condition affecting particularly women in their sixties presenting with a high disease burden with quality-of-life impairment. Limited understanding of the risk factors and genetic associations represents a barrier towards effective management.</jats:p> </jats:sec> <jats:sec> <jats:title>Methods</jats:title> <jats:p>We used GWAS datasets for respiratory system and other diseases, and behavioral phenotypes from UK Biobank, FinnGen, Global Biobank Meta-analysis Initiative and Psychiatric Genomics Consortium. We identified pleiotropic genetic associations with chronic cough using linkage disequilibrium score regression, pleiotropy analysis, and Bayesian co-localization analysis. We conducted Mendelian Randomization analysis to determine the association of brain regional volumes with chronic cough risk.</jats:p> </jats:sec> <jats:sec> <jats:title>Results</jats:title> <jats:p>We found 19 significant genetic correlations between chronic cough and various risk factors and associations. Among 74 pleiotropic genomic loci identified, the 4p14 locus had the strongest effect on cough-associated asthma, with RFC1 linked to the Cerebellar Ataxia, Neuropathy and Vestibular Areflexia Syndrome. Gene enrichment analyses highlighted central nervous system and ion channel activity in the pathogenesis of cough. A reduction in the volume of isthmus cingulate, thalamus proper and pallidum was associated with an increased risk of chronic cough. In aging-associated cough, the direct effect of aging on chronic cough was an increase odds-ratio of 1.044, with an impact of a reduction in left pallidum volume of OR of 0.902.</jats:p>

  • Abstract
  • Publisher Web Link
  • Cite
• Journal article
  Doe G, Banya W, Edwards G, Topalovic M, El-Emir E, Evans RA, Russell R, Smets E, Van Orshoven K, Sylvester KP, Sunjaya AP, Scott DA, De Vos M, Elmahy A, Taylor SJC, Hutchinson A, Hopkinson NS, Morgan M, Kon SS, Patel S, Jarrold I, Kennington E, Sehdev S, Spain N, Prevost AT, Man WD-Cet al., 2025,

  Response: To the Comment on AI-Assisted Spirometry Interpretation in Primary Care: A Randomized Controlled Trial

  , NEJM AI, Vol: 2, ISSN: 2836-9386
  • Publisher Web Link
  • Cite
• Journal article
  MacLeod MA, Knott KD, Nicol ED, Wedzicha JAet al., 2025,

  Reply to Liu et al.: Considerations on Stratified Analysis and Biomarker Use in CAD Detection in COPD.

  , Am J Respir Crit Care Med
  • Author Web Link
  • Cite
• Journal article
  Cheng W-H, Chung KF, Lin T-Y, Chuang H-Cet al., 2025,

  Editorial: Eosinophilic inflammation in chronic lung diseases: emerging molecular insights and therapeutic strategy

  , FRONTIERS IN MEDICINE, Vol: 12
  • Cite
• Journal article
  Laverty A, Hopkinson NS, 2025,

  What is the relationship between population health and voting patterns: an ecological study in England

  , BMJ Open Respiratory Research, ISSN: 2052-4439

  BackgroundHealth is a fundamental issue in politics and an area where governments hold significant levers of influence. Countries in Europe have seen increased support for populist political parties, with some evidence linking support for these parties to health metrics. We aimed to establish if there is an association between health metrics and patterns of voting in England, particularly in relation to a recently established political party, Reform UK, in the 2024 general election.MethodsWe conducted a cross-sectional ecological study with data from all constituencies in England (n=543). We conducted Pearson correlations and linear regression between proportion of eligible votes for Reform UK and estimated prevalence of 20 common non-communicable diseases, including obesity, COPD, asthma, type 2 diabetes and depression.ResultsConstituencies electing Reform MPs (n=5/543) had the highest prevalence of Asthma (7.44%) and COPD (2.85%). Across the country, adjusting for age, sex and deprivation, a 10% increase in the party’s vote share was associated with a +0.261% (95% Confidence Interval 0.213 to 0.309) prevalence of COPD, a +0.113% (95%CI 0.026 to 0.201) prevalence of asthma and a +1.479% (95%CI 1.239 to 1.720) increase in obesity prevalence. ConclusionsAt a constituency level, poor health, in particular conditions associated with breathlessness, is associated with a greater proportion of votes for Reform UK.

  • Abstract
  • Cite
• Journal article
  Tran XN, Lee Y-L, Lin Y-C, Chang T-Y, Chang L-T, Ho K-F, Chuang K-J, Chung KF, Chang J-H, Chuang H-Cet al., 2025,

  Associations of meteorological factors and obesity on pediatric asthma hospitalization

  , PEDIATRIC RESEARCH, ISSN: 0031-3998
  • Cite
• Journal article
  Caramori G, Rossi F, Adcock IM, 2025,

  GDF11: A promising new drug target for pulmonary fibrosis?

  , MOLECULAR THERAPY, Vol: 33, Pages: 4676-4679, ISSN: 1525-0016
  • Cite
• Journal article
  Hutchinson A, Russell R, Cummings H, Usmani O, MacFadyen S, Cohen J, Morris T, Muellerova H, Xu Y, Hellens G, Roy K, Crooks MGet al., 2025,

  Correction: Exploring patients' and carers' experiences, understandings and expectations of COPD exacerbations: an interview study (vol 9, BJGPO20240026, 2025)

  , BJGP OPEN, Vol: 9
  • Cite
• Journal article
  Toumpanakis D, Usmani OS, 2025,

  Innovation in technologies for monitoring lung function in patients with respiratory disease.

  , Breathe (Sheff), Vol: 21, ISSN: 1810-6838

  Pulmonary function testing is a pillar of respiratory medicine, contributing to the diagnosis and monitoring of respiratory diseases and supporting therapeutic decisions. The aim of this review is to summarise advances in the field of lung function monitoring, presenting both innovation in current everyday lung function testing, as well as newer physiological and functional imaging techniques. We highlight the potential clinical utility of novel digital tools, such as smart inhalers, wearables and sensors, that enable continuous real-time monitoring of lung physiological parameters and assessment of therapeutic interventions. Finally, current evidence for the application of artificial intelligence tools, such as machine- and deep-learning algorithms, in lung function interpretation is discussed.

  • Abstract
  • Author Web Link
  • Cite
• Journal article
  Guo S, Yang Z, Liu M, Ip MSM, Song W-J, Chung KFet al., 2025,

  Assessment of cough in asthma patients attending clinic using the cough questionnaire for asthma (CQA)

  , JOURNAL OF THORACIC DISEASE, Vol: 17, ISSN: 2072-1439
  • Cite
• Journal article
  Valikhani M, Mortaz E, Molodi NA, Adcock IM, Tabarsi Pet al., 2025,

  Influenza-related invasive pulmonary aspergillosis in an infectious disease ward at a pulmonary referral center in Iran

  , BMC INFECTIOUS DISEASES, Vol: 25
  • Cite
• Journal article
  Perugini V, Rhee CK, Moon J-Y, Pei Yee T, Ra SW, Pirina P, Yoo KH, Navarrete BA, Gouder C, Pacheco A, Navarro-Rolon A, Harlander M, Lapperre T, Loh SCH, Fole D, Naval E, Palacios PJR, Miravitlles M, Usmani Oet al., 2025,

  Assessment of peak inspiratory flow in patients with chronic obstructive pulmonary disease: a multicentre, observational, prospective, real-life study

  , BMJ OPEN RESPIRATORY RESEARCH, Vol: 12
  • Cite
• Journal article
  Kelly JL, Turnbull CD, Newson R, Dobson M, Hedley EL, Alqarni AS, Nevinson A, Dawson D, Nickol A, West S, Talbot NP, Rahman NM, Stradling J, Morrell MJet al., 2025,

  Vibrotactile positional therapy for the treatment of positional obstructive sleep apnoea: a multicentre, randomised controlled trial

  , THORAX, ISSN: 0040-6376
  • Cite
• Report
  Hopkinson N, 2025,

  TOBACCO ENDGAME: Using lessons from the UK experience to develop a knowledge toolkit for tobacco control

  , ERS report, Publisher: European Respiratory Society
  • Publisher Web Link
  • Cite
• Journal article
  Cho PSP, Birring SS, Mcdowell C, Brown T, Hull JH, Smith JA, Guilleminault L, Kardos P, van den Berg JW, Domingo C, Marsden P, Idzko M, Lavorini F, Martin MJ, Slinger C, Demoulin-Alexikova S, Stolz D, Michels AJ, Tirzite M, Gradauskiene B, Winck JC, Emilsson OI, Kaltsakas G, Hyldgaard C, Chung KF, Millqvist E, Narayanan A, Gossage L, Buchwald-Mackintosh K, Siegert RJ, Schulte M, Nair A, Nelson J, Parker SM, Dabrowska M, Morice A, Dupont LJA, McGarvey Let al., 2025,

  The NEuroCOUGH Chronic Cough Registry: a protocol for a pan-European observational study

  , ERJ OPEN RESEARCH, Vol: 11
  • Cite
  • Citations: 1
• Journal article
  Lin Y, Chen R, Ge Y, Liu X, Chung KF, Zhang JJet al., 2025,

  Nitrated Fatty Acids and Susceptibility of COPD to Air Pollution: Evidence from a Randomized Crossover Study

  , ENVIRONMENT & HEALTH, Vol: 3, Pages: 1107-1114, ISSN: 2833-8278
  • Cite
• Journal article
  Rattu A, Dixey P, Charles D, Brightling C, Chung KF, Bossios A, Bourdin A, Djukanovic R, Dahlen S-E, Fleming L, Chaudhuri R, Melen E, Deschildre A, Pilette C, Koppelman GH, Exley A, Anckers F, Miller S, Nielsen H, Williams C, Khaleva E, Roberts Get al., 2025,

  Predictors of Response to Biologics for Severe Asthma: A Systematic Review and Meta-Analysis

  , ALLERGY, ISSN: 0105-4538
  • Cite
• Journal article
  ALZAHRANI A, Majrshi M, Alghamdi S, Alasmari AM, Alshehri ZD, Alahmadi FH, Qahtani SA, Alhawsawi A, Alasimi AH, Eilayyan O, Polkey MI, Birring SS, Hopkinson Net al., 2025,

  Perceptions and clinical practice around use of airway clearance devices in chronic obstructive pulmonary disease

  , Journal of Medical Rehabilitation Science, Vol: 2, Pages: 82-93, ISSN: 2961-421X

  Background: Effective airway clearance is a critical component of COPD management. Airway clearance devices (ACDs) can assist this, but their effectiveness relies on consistent use in clinical practice.Objectives: To identify awareness and clinical practice related to device use for people with COPD among respiratory therapists and physiotherapists in Saudi Arabia.Design: A cross-sectional survey.Setting: Primary and secondary care in Saudi ArabiaMaterial and Methods: An online survey was conducted among respiratory care and physiotherapy practitioners working in various healthcare settings across Saudi Arabia. The survey assessed familiarity with, attitudes towards, and utilisation of different types of ACDs in different clinical scenarios.Results: A total of 423 healthcare practitioners were invited to complete the survey, which included 43% female participants, a median age range of 20-30 years, 89.4% Saudi citizens, 82.5% with a bachelor’s degree, 84.2% who are respiratory therapists, and 58.9% employed in governmental hospitals. Almost all participants were aware of at least one ACD, with Flutter devices (58%) being the most recognised, followed by Acapella (30%). 77.5% of participants reported always or usually using devices in patients with daily difficulty in clearing thick sputum, but there was less consistency where the sputum burden was not as severe. The Acapella device was preferred by 56%, with 18% preferring the Flutter. 85% of participants reported basing device use on clinical practice guidelines, with the GOLD guidelines being the most cited.Conclusion: Awareness of sputum clearance devices is high among this group of healthcare professionals in Saudi Arabia, but variation in practice highlights the need for further research.

  • Abstract
  • Cite
• Journal article
  Usmani OS, Martinez FJ, Pandya H, Camiolo M, Bednarczyk A, Kucz K, Kokot M, Gottfridsson C, Aurivillius M, Pettersson L, Mei J, Skansen K, Bell JL, Petullo D, Collison K, Bondarov P, Jassal M, Patel Met al., 2025,

  Safety of budesonide/glycopyrronium/formoterol fumarate dihydrate delivered by HFO-1234ze versus HFA-134a in chronic obstructive pulmonary disease: a phase 3, multi-site, randomised, double-blind, parallel-group, active-comparator study

  , EClinicalMedicine, Vol: 87, ISSN: 2589-5370

  Background Pressurised metered dose inhalers (pMDIs) contain a hydrofluorocarbon propellant, such ashydrofluoroalkane-134a (HFA-134a), which is known to have global warming potential (GWP). Transitioning pMDIs to propellants with lower GWP will reduce the environmental impact of pMDIs. This study assessed the safety of a near-zero GWP propellant, hydrofluoroolefin-1234ze (HFO-1234ze), compared with HFA-134a when used in the delivery of budesonide/glycopyrronium/formoterol fumarate dihydrate (BGF) in participants with chronicobstructive pulmonary disease (COPD). The results of this study advance our understanding of the safety ofHFO-1234ze compared with HFA-134a.Methods This phase 3, double-blind, parallel-group study (ClinicalTrials.gov NCT05573464) across 9 countries (Argentina, Bulgaria, Canada, Germany, Mexico, Poland, Turkey, the United Kingdom, the United States) included participants (aged 40–80 years) with physician-diagnosed COPD using dual or triple inhaledmaintenance therapies, COPD Assessment Test score ≥10, ≥10 pack-years smoking history, and no comorbiddiagnosis of asthma or other clinically significant diseases impacting study outcomes. Participants wererandomised (1:1) to receive either BGF HFO-1234ze or BGF HFA-134a (two inhalations of 160/7⋅2/5⋅0 μg twicedaily) for 12 weeks in the main safety analysis set (or 52 weeks [first 120 participants per treatment]). Safetyendpoints included the incidence of adverse events (AEs), measures of vital signs, clinical laboratory tests, and electrocardiograms.Findings Participants were recruited between 27 September 2022 and 19 May 2023. A total of 874 participants were screened. Of 558 treated participants (mean [standard deviation] age, 67⋅0 [7⋅4] years; male, 315 [56⋅5%]) in the 12-week safety analysis set, 280 received BGF HFO-1234ze, and 278 received BGF HFA-134a. The AE incidence was balanced between formulations in the 12-week (HFO-1234ze, 124 [44⋅3%]; HFA-134a

  • Abstract
  • Publisher Web Link
  • Cite

This data is extracted from the Web of Science and reproduced under a licence from Thomson Reuters. You may not copy or re-distribute this data in whole or in part without the written consent of the Science business of Thomson Reuters.